• 1
    Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998; 93: 18601866.
  • 2
    Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002; 8: 317324.
  • 3
    Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17: 12731281.
  • 4
    Högenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther. 2003; 18: 415423.
  • 5
    Ogata H, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 12551262.
  • 6
    Marion JF, Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis and Crohn's disease. In: Kirsner JB, ed. Inflammatory Bowel Disease, 5th ed. Philadelphia: W.B. Saunders; 2000: 315325.
  • 7
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, a randomized study. N Engl J Med. 1987; 317: 16251629.
  • 8
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 24622476.
  • 9
    Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010; 45: 11291137.
  • 10
    Naganuma M, Ichikawa H, Inoue N, et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol. 2010; 45: 936943.
  • 11
    Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease — a long-term follow-up. Am J Gastroenterol. 2006; 101: 10481056.
    Direct Link:
  • 12
    Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 589597.
  • 13
    Yamamoto S, Nakase H, Matsuura M, et al. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol. 2011; 45: 526530.
  • 14
    Naganuma M, Fujii T, Watanabe M, et al. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011; 46: 129137.